LGR5
LGR5 (Leucine-rich repeat-containing G protein-coupled receptor 5) is a protein on the cell surface. The public catalogues list it as a drug target, a biomarker and an antigen, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Sarcomas.
Overview
Receptor for R-spondins that potentiates the canonical Wnt signalling pathway and acts as a stem cell marker of the intestinal epithelium and the hair follicle. Upon binding to R-spondins (RSPO1, RSPO2, RSPO3 or RSPO4), associates with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signalling pathway to increase expression of target genes. In contrast to classical G protein-coupled receptors, does not activate heterotrimeric G proteins to transduce the signal.
CIViC holds 3 clinical evidence items and 0 assertions across 2 variants, naming Fluorouracil. In OnCo, 1 product record names it (Petosemtamab).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · LGR5 (Leucine-rich repeat-containing G protein-coupled receptor 5) is a protein on the cell surface. The public catalogues list it as a drug target, a biomarker and an antigen, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Sarcomas.
- 1 · What it is
LGR5 (Leucine-rich repeat-containing G protein-coupled receptor 5) is a protein on the cell surface. The public catalogues list it as a drug target, a biomarker and an antigen, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Sarcomas.
- 2 · What goes wrong in cancer
Receptor for R-spondins that potentiates the canonical Wnt signalling pathway and acts as a stem cell marker of the intestinal epithelium and the hair follicle.
- 3 · How drugs use it
No product in this corpus aims at LGR5 yet. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
External identifiers
Sources: HGNC HGNC:4504 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O75473 (protein name, function text, keywords and locations (REST API)); CIViC gene LGR5 (3 evidence items, 0 assertions, 2 variants; diseases: Colorectal Cancer, Oral Squamous Cell Carcinoma, Sarcoma (GraphQL API, CC0))
Biology
Receptor for R-spondins that potentiates the canonical Wnt signalling pathway and acts as a stem cell marker of the intestinal epithelium and the hair follicle. Upon binding to R-spondins (RSPO1, RSPO2, RSPO3 or RSPO4), associates with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signalling pathway to increase expression of target genes. In contrast to classical G protein-coupled receptors, does not activate heterotrimeric G proteins to transduce the signal. Involved in the development and/or maintenance of the adult intestinal stem cells during postembryonic development. Location: Cell membrane; Golgi apparatus, trans-Golgi network membrane (UniProt). Locus 12q21.1 (HGNC).
- Colorectal cancer: CIViC evidence names this disease
- Sarcomas: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 3 clinical evidence items on its variants; a membrane or secreted protein (UniProt keywords) that 1 antibody-based OnCo product name. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Oral Squamous Cell Carcinoma.
Latest papers
topQuery for this target: (TITLE:"LGR5" OR ABSTRACT:"LGR5" OR TITLE:"leucine rich repeat containing G protein-coupled receptor 5" OR ABSTRACT:"leucine rich repeat containing G protein-coupled receptor 5" OR TITLE:"Leucine-rich repeat-containing G protein-coupled receptor 5" OR ABSTRACT:"Leucine-rich repeat-containing G protein-coupled receptor 5" OR TITLE:"HG38" OR ABSTRACT:"HG38" OR TITLE:"GPR67" OR ABSTRACT:"GPR67" OR TITLE:"GPR49" OR ABSTRACT:"GPR49") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LGR5, not a curated reading list.
Similar pages
not linked directly; found by shared links- TermLGR5
Shares Petosemtamab, Wnt / β-catenin, Colorectal cancer.
- PersonEric R. Fearon
Shares Wnt / β-catenin, Colorectal cancer.
- TrialA Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Shares Petosemtamab, Colorectal cancer.
- TrialStudy of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorecta
Shares Petosemtamab, Colorectal cancer.
- TrialStudy of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metast
Shares Petosemtamab, Colorectal cancer.
- TargetRNF43
Shares Wnt / β-catenin, Colorectal cancer.
- TargetAPC
Shares Wnt / β-catenin, CIViC, Colorectal cancer.
- TermConsensus molecular subtypes (CMS1-4)
Shares Wnt / β-catenin, Colorectal cancer.